Literature DB >> 15810955

Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.

I Vanden Bempt1, V Vanhentenrijk, M Drijkoningen, I Wlodarska, P Vandenberghe, C De Wolf-Peeters.   

Abstract

AIMS: To evaluate the HER-2/neu status at the mRNA and DNA level of breast carcinomas and to compare it with HER-2/neu receptor overexpression by immunohistochemistry (IHC). METHODS AND
RESULTS: In 32 invasive breast carcinomas, frozen tissue was available for real-time detection of HER-2/neu mRNA levels by reverse transcription-polymerase chain reaction (RT-PCR). Corresponding paraffin sections were examined by IHC and fluorescence in-situ hybridization (FISH). Thereby, different IHC and FISH procedures were compared. Using microwave epitope retrieval, all 32 cases scored 3+ on IHC, whereas only 28 out of 32 cases scored IHC 3+ using water bath epitope retrieval. All of these 28 cases showed increased levels of HER-2/neu mRNA. Dual-colour FISH analysis showed corresponding gene amplification in all 28 cases, with two cases showing a peculiar amplification pattern. In the remaining four cases, scoring IHC 2+ using water bath epitope retrieval, mRNA levels were not elevated. Three cases did not have gene amplification and one case showed low-level HER-2/neu gene amplification. All four carcinomas showed chromosome 17 polysomy.
CONCLUSIONS: Real-time RT-PCR is accurate in selecting breast carcinoma cases scoring 3+ by IHC with high-level gene amplification. Results obtained by dual-colour FISH suggest that mechanisms leading to HER-2/neu receptor overexpression may be different between carcinomas scoring 2+ and 3+ on IHC, with polysomy 17 found in the former and gene amplification in the latter.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15810955     DOI: 10.1111/j.1365-2559.2005.02112.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  16 in total

1.  Biomedical application of fuzzy association rules for identifying breast cancer biomarkers.

Authors:  F J Lopez; M Cuadros; C Cano; A Concha; A Blanco
Journal:  Med Biol Eng Comput       Date:  2012-05-24       Impact factor: 2.602

2.  Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.

Authors:  Aziza Nassar; Andras Khoor; Reshmitha Radhakrishnan; Anu Radhakrishnan; Cynthia Cohen
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  Comparison of fluorescence in situ hybridization and immunohistochemistry for assessment of HER-2 status in breast cancer patients.

Authors:  Lin Wang; Xiaobei Wang; Xiu Nie; Ling Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

4.  Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer.

Authors:  Laura Casorzo; Mara Corigliano; Paolo Ferrero; Tiziana Venesio; Mauro Risio
Journal:  Diagn Pathol       Date:  2009-11-04       Impact factor: 2.644

5.  The epidermal growth factor receptor family in breast cancer.

Authors:  Angelos K Koutras; T R Jeffry Evans
Journal:  Onco Targets Ther       Date:  2008-09-01       Impact factor: 4.147

Review 6.  Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

Authors:  Monica M Reinholz; Amy K Bruzek; Daniel W Visscher; Wilma L Lingle; Matthew J Schroeder; Edith A Perez; Robert B Jenkins
Journal:  Lancet Oncol       Date:  2009-03       Impact factor: 41.316

7.  Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.

Authors:  J Lehmann-Che; F Amira-Bouhidel; E Turpin; M Antoine; H Soliman; L Legres; C Bocquet; R Bernoud; E Flandre; M Varna; A de Roquancourt; L-F Plassa; S Giacchetti; M Espié; C de Bazelaire; L Cahen-Doidy; E Bourstyn; A Janin; H de Thé; P Bertheau
Journal:  Br J Cancer       Date:  2011-05-03       Impact factor: 7.640

8.  Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma.

Authors:  Fabíola E Rosa; Sara M Silveira; Cássia G T Silveira; Nádia A Bérgamo; Francisco A Moraes Neto; Maria A C Domingues; Fernando A Soares; José R F Caldeira; Silvia R Rogatto
Journal:  BMC Cancer       Date:  2009-03-23       Impact factor: 4.430

9.  Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer.

Authors:  Weiguo Sui; Minglin Ou; Jiejing Chen; Youhua Wan; Hongbo Peng; Minfang Qi; He Huang; Yong Dai
Journal:  World J Surg Oncol       Date:  2009-11-09       Impact factor: 2.754

10.  Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.

Authors:  Manal F Ismail; Magdy Sayed Aly; Hussein M Khaled; Hanaa M Mohamed
Journal:  Ger Med Sci       Date:  2009-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.